ArticleApplied biosafety : journal of the American Biological Safety Association2024
A Sensitivity Study for Interpreting Nucleic Acid Sequence Screening Regulatory and Guidance Documentation: Toward a Foundational Synthetic Nucleic Acid Sequence Screening Framework.
Article in Applied biosafety : journal of the American Biological Safety Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Red-teaming as an imperative for strengthening synthetic nucleic acid screening.Frontiers in bioengineering and biotechnology · 2026Review
- Implementing emerging customer screening standards for nucleic acid synthesis.Frontiers in bioengineering and biotechnology · 2026Article
- Beyond sequence similarity: toward function-based screening of nucleic acid synthesis.Frontiers in bioengineering and biotechnology · 2026Article
- ADAPT: a programme for the advanced detection of AI-enabled pathogenic threats.Frontiers in bioengineering and biotechnology · 2026Article
- A perspective and demonstration of an approach to screening synthetic nucleic acid orders containing short nucleic acid sequences.Frontiers in bioengineering and biotechnology · 2026Article
- Why implementation gaps could undermine synthetic nucleic acid oversight.Frontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The primary objectives of this study were to develop an objective nucleic acid sequence screening framework and to leverage the framework for an empirical sensitivity study that measures the impact of ambiguities in regulatory and guidance documentation regarding the control of synthetic nucleic acids and screening of nucleic acid orders. Methods: Foundational risk levels were constructed using the bioinformatic sequencing screening tool UltraSEQ. The risk levels range from high (corresponding to regulated sequences) to low (corresponding to nonregulated sequences of concern) to no-risk. A representative sequence data set (141,651 sequences) was constructed from publicly available synthetically derived sequences, and the percentage sequences in each risk level was determined, followed by the impact of changing key UltraSEQ parameters. Results: The results of this study show that no-risk sequences represent 90-92% of sequences, and nonregulated sequences of concern represented 7-9% of the sequences regardless of the parameters. The parameter with the biggest impact on the number of sequences flagged was the minimum hit homology level, followed by minimum sequence region length, and finally uniqueness of the hit to a select agent sequence. Conclusion: The results of this empirical study provide a greater understanding for gene synthesis providers, biosafety and biosecurity practitioners, and the scientific community regarding the impact of various interpretations of regulatory and guidance documentation. The risk level framework provides a foundation to build upon for nucleic acid sequence screening as the threat landscape evolves. However, additional development is needed to build tools that connect predictions across sequences and orders to provide contextual risk-based predictions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.